Table 1.
Characteristics of the study group
| ID ( +) n = 70 | ID (-) n = 77 | p | ||
|---|---|---|---|---|
| Age, y, median (range) | 7 (4–13) | 9 (4–13) | ||
| < 1 years old | 4 (5.7%) | 2 (2.6%) | 0.41 | |
| 1–5 years old | 24 (34.3%) | 22 (28.6%) | ||
| 6–10 years old | 16 (22.9%) | 17 (22.1%) | ||
| 11–15 years old | 17 (24.3%) | 28 (36.4%) | ||
| 16–18 years old | 9 (12.9%) | 8 (10.4%) | ||
| Sex | ||||
| Female | 33 (47.1%) | 36 (46.8%) | 0.96 | |
| Male | 37 (52.9%) | 41 (53.2%) | ||
| BMI | ||||
| 17.2 (16.1–18.5) | 17.2 (15.9–19.6) | 0.88 | ||
| Severity of COVID-19 | ||||
| Asymptomatic | 32 (45.7%) | 10 (13.0%) | < 0.01 | |
| Mild | 27 (38.6%) | 37 (48.1%) | ||
| Moderate | 8 (11.4%) | 24 (31.2%) | ||
| Severe | 3 (4.3%) | 6 (7.8%) | ||
| MIS-C | ||||
| 0 (0.0%) | 1 (1.3%) | |||
| Immunodeficiency | ||||
| Tumors | 44 (62.9%) | N/A | ||
| Chemotherapy | 38 (54.3%) | |||
| Radiotherapy | 2 (2.9%) | |||
| Chemo- and radiotherapy | 4 (5.7%) | |||
| Liver transplantation + PTLD | 2 (2.9%) | |||
| Steroids + chemotherapy | ||||
| Liver transplantation | 8 (11.4%) | |||
| Steroids + other immunosuppressants | ||||
| Kidney transplantion | 7 (10.0%) | |||
| Steroids + other immunosuppressants | ||||
| Ulcerative colitis | 4 (5.7%) | |||
| Steroids + azathioprine | 3 (4.3%) | |||
| Steroids + vedolizumab | 1 (1.4%) | |||
| Multiple sclerosis | 2 (2.9%) | |||
| Steroids | 1 (1.4%) | |||
| Steroids + natalizumab | 1 (1.4%) | |||
| Devic’s disease | 1 (1.4%) | |||
| Immunoglobulins | ||||
| Primary immunodeficiency | 2 (2.9%) | |||
| Wiskott–Aldrich syndrome | 1 (1.4%) | |||
| DiGeorge syndrome | 1 (1.4%) | |||
| Allergic diseases | ||||
| 0 (0.0%) | 22 (28.6%) | < 0.01 | ||
| Vaccination against SARS-CoV-2 | ||||
| 3 (4.3%) | 20 (26.0%) | < 0.01 | ||
BMI, body mass index; COVID-19, coronavirus disease 2019; ID ( +),children with immunodeficiency; ID (-), children without immunodeficiency; MIS-C, multisystem inflammatory syndrome in children; PTLD, post-transplant lymphoproliferative disease